Innovation Pharma reflects what they are doing. Us
Post# of 72447
(Total Views: 222)
Posted On: 06/08/2017 11:10:25 AM
Innovation Pharma reflects what they are doing. Used to be cell-based medicine. Now targeting small molecules. Re-brand company closer to its true roots of innovative drug candidates.
Dr. Bertolino:
Brilacidin: 2a for UP now nearing completion. Interim results very encouraging. Endoscopic response in half the patients so far. Almost all have clinically meaningful improvements. Endoscopic data reflects ability of Bril to clear GI tract mucosa. 3 patients who completed continue to tolerate it well. Patients say improved quality of life. Drug concentrations in plasma remain in favorable range even with doubling of dose. Cohort C completes this month.
OM- also progressing well. Recruitment steady now, 1 new patient per week. Interim results very encouraging. Only 22.2% had severe OM in Bril group as opposed to 70% in control group. Double-blind study.
Whenever we've testing Bril it shows signs of working and impresively so.
Can conclude trial in timely fashion this year.
OM findings further establish Bril's potential in many areas. Can be broadly applied particularly as topical agent.
Dr. Bertolino:
Brilacidin: 2a for UP now nearing completion. Interim results very encouraging. Endoscopic response in half the patients so far. Almost all have clinically meaningful improvements. Endoscopic data reflects ability of Bril to clear GI tract mucosa. 3 patients who completed continue to tolerate it well. Patients say improved quality of life. Drug concentrations in plasma remain in favorable range even with doubling of dose. Cohort C completes this month.
OM- also progressing well. Recruitment steady now, 1 new patient per week. Interim results very encouraging. Only 22.2% had severe OM in Bril group as opposed to 70% in control group. Double-blind study.
Whenever we've testing Bril it shows signs of working and impresively so.
Can conclude trial in timely fashion this year.
OM findings further establish Bril's potential in many areas. Can be broadly applied particularly as topical agent.
(6)
(0)